

---

## Intensity Therapeutics, Inc. to Present at the Redefining Early Stage Investments Conference

**Norwalk, CT. – September 12, 2013-** Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Redefining Early Stage Investments (RESI) Conference on Monday, September 16, 2013 at the State Room, 60 State Street 33<sup>rd</sup> Floor, Boston MA. Mr. Bender will provide an overview of the Company at 11:00 a.m. (EST). Mr. Bender will be available for one-on-one meetings with investors participating in conference before and after his presentation.

### About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Late stage cancer consists of well-defined visible tumors and unseen micro-metastases. To have an effective treatment one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics is developing such a treatment approach. The Company creates novel, proprietary formulations of proven chemotherapy drugs. The technology increases the drug's tissue dispersion and cell penetration properties. These products when injected directly into the primary tumor and the major visible metastases result in significantly greater survival compared to conventionally delivered chemotherapy. Further information can be found at [www.intensitytherapeutics.com](http://www.intensitytherapeutics.com)

### Contact:

Media & Investors:

Lewis Bender

President & CEO

40 Richards Avenue

Norwalk, CT 06854

Tel. (203) 604-6858

Email: [lbender@intensitytherapeutics.com](mailto:lbender@intensitytherapeutics.com)